title: [Late potentials of the heart ventricles and a method of spectral mapping for evaluating the action of dalargin in intensive therapy].
abstract: The data of 114 examinations of 38 patients with respiratory failure of different genesis have been presented. The method used was that of averaging the ECG signal with analysis of late ventricular potentials and parameters of spectral mapping, as well as analysis of the R-R intervals. The patients were examined initially, 30-45 min after intravenous injection of 1 mg dalargin and 16-20 hours later. The results have shown that there were differences in the changes of a number of basic characteristics of the QRS complex spectrum. In 18 cases (21%) signs of late potentials have been recorded, 14 of them (78%) in the group with decreased total spectral density. A shift of extremums by the beginning of QRS was observed. Statistical and spectral characteristics of the R-R intervals changed in one direction. It has been shown that dalargin has a complex effect on electrophysiological myocardial properties. The use of the method of ECG signal averaging and its different modifications broadens considerably the quality of evaluation of the drug effect in the heart. The technique of spectral-time mapping simplifies the diagnosis of late potentials and elucidates their inner structure.
authors: G G
authors: GG
authors: Ivanov
authors: V V
authors: VV
authors: Kovtun
authors: V D
authors: VD
authors: Slepushkin
authors: A Iu
authors: AIu
authors: Perov
authors: M B
authors: MB
authors: Zakhvatkin
authors: Iu V
authors: IuV
authors: Pichugin
authors: D A
authors: DA
authors: Dzhabarov
authors: D A
authors: DA
authors: Ostapchenko
mesh_terms: D000328:Adult; D003422:Critical Care; D004562:Electrocardiography / Q000187:drug effects*; D016308:Enkephalin, Leucine-2-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006352:Heart Ventricles / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D007275:Injections, Intravenous; D012131:Respiratory Insufficiency / Q000188:drug therapy* / Q000503:physiopathology; D013565:Sympatholytics / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D013565:Sympatholytics; D016308:Enkephalin, Leucine-2-Alanine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
vernacular_title: Pozdnie potentsialy zheludochkov serdtsa i metod spektral'nogo kartirovaniia dlia otsenki deĭstviia dalargina v intensivnoĭ terapii.